Nasal mRNA Therapy: Anti-Viral Cytokine Response

Future Studies & Next Steps in Nasal ETH47 Progress:

Here’s a breakdown of what’s next, based on the provided text:

1. Phase 2a Clinical Trial ‍(Currently Ongoing):

* Design: A rhinovirus challenge trial in patients with mild‍ to moderate asthma. This means patients will be intentionally exposed to rhinovirus under controlled conditions.
*⁢ Goals: To determine if ETH47 can:
* ⁢ Prevent ⁤worsening of asthma symptoms.
*‍ Reduce viral load in the nose and lungs.
* Prevent reduction in lung function after⁤ viral infection.
* Meaning: This trial is designed to provide strong evidence that ETH47 works ⁤as intended -‍ by directly preventing virus-triggered ‍asthma⁣ symptoms.

2. Formulation Development:

* Goal: To develop a‍ dry powder formulation of⁤ ETH47 using spray drying technology (currently using mRNA/LNP spray drying). This would ⁢likely improve ⁤ease of use and stability.

3.Nasal mRNA Vaccine Development:

* ⁤ Leveraging ⁢ETH47’s Safety: The company is exploring using the same technology behind ETH47⁤ to‍ create nasal mRNA vaccines, capitalizing on the observed safety and biological activity.

4. Platform Expansion & Collaboration:

* SNIM RNA/SNaP LNP platform: Thier core technology is attracting interest from othre researchers ⁤and companies.
* Strategic Partnerships: They’ve partnered ⁣with Thermo⁣ Fisher Scientific and Evonik⁣ to expand manufacturing capabilities (both non-GMP and GMP scale-up).
* Broader Therapeutic Applications: They are ⁤investigating the potential of their platform for⁣ other mRNA therapies beyond asthma, including:
* Respiratory and infectious⁤ diseases
⁣ * Regenerative medicine (musculoskeletal and neuroscience areas)

In essence, the next steps involve rigorously testing ETH47’s efficacy in a controlled setting, improving its delivery method, and expanding the request of their ⁢underlying technology to a wider range of diseases and therapies.